Acta biochimica et biophysica Sinica · 2009
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Feng Jifeng, Sun Xinchen, Sun Ning, Qin Shukui, Li Fan, Cheng Hongyan, Chen Baoan, Cao Yuandong, Ma Jun, Cheng Lu, Lu Zuhong, Ji Jiazhong, Zhou Yingfeng
Аннотация
DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the Aright curved arrow G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungCisplatinDNA-Binding ProteinsDeoxycytidineDocetaxelEndonucleasesFemaleGene FrequencyGenotypeHumansLogistic ModelsLung NeoplasmsMaleMiddle AgedNuclear ProteinsPaclitaxelPolymorphism, Single NucleotideTaxoidsTranscription FactorsTreatment OutcomeVinblastineVinorelbineXeroderma Pigmentosum Group A ProteinGemcitabineDNA Excision Repair Protein ERCC-5